Pharmacoresistant epilepsy and nanotechnology
Argelia Rosillo-de la Torre, Gabriel Luna-Bárcenas, Sandra Orozco-Suárez, Hermelinda Salgado-Ceballos, Perla García, Alberto Lazarowski, Luisa Rocha · Frontiers in Bioscience-Elite · 2014
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
Frontiers in Bioscience-Elite · Frontiers Media · article · 2014
Abstract
Epilepsy is one of the most common chronic neurological disorders. Furthermore, it is associated to diminished health-related quality of life and is thus considered a major public health problem. In spite of the large number of available and ongoing development of several new antiepileptic drugs (AEDs), a high percentage of patients with epilepsy (35-40%) are resistant to pharmacotherapy. A hypothesis to explain pharmacoresistance in epilepsy suggests that overexpression of multidrug resistance proteins, such as P-glycoprotein, on the endothelium of the blood brain barrier represents a challenge for effective AED delivery and concentration levels in the brain.
Proven therapeutic strategies to control pharmacoresistant epilepsy include epilepsy surgery and neuromodulation. Unfortunately, not all patients are candidates for these therapies. Nanotechnology represents an attractive strategy to overcome the limited brain access of AEDs in patients with pharmacoresistant epilepsy. This manuscript presents a review of evidences supporting this idea.
Open the resolved locator · 10.2741/709
Metadata licence: OpenAlex metadata (CC0)